Omnicell (NASDAQ:OMCL) Updates Q4 Earnings Guidance

Omnicell (NASDAQ:OMCL) issued an update on its fourth quarter earnings guidance on Wednesday morning. The company provided earnings per share guidance of $0.55-$0.62 for the period, compared to the consensus earnings per share estimate of $0.47. The company issued revenue guidance of $295-$305 million, compared to the consensus revenue estimate of $287.85 million. Omnicell also updated its FY 2024 guidance to 1.650-1.720 EPS.

Omnicell Price Performance

Shares of OMCL stock traded up $0.03 during trading hours on Friday, reaching $48.67. 683,792 shares of the company were exchanged, compared to its average volume of 528,146. Omnicell has a fifty-two week low of $25.12 and a fifty-two week high of $55.74. The stock’s fifty day moving average is $43.34 and its two-hundred day moving average is $35.32. The company has a market cap of $2.24 billion, a price-to-earnings ratio of -124.79, a P/E/G ratio of 58.48 and a beta of 0.83. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.05 and a quick ratio of 2.22.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, August 1st. The company reported $0.51 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.37. Omnicell had a negative net margin of 1.66% and a positive return on equity of 2.55%. The company had revenue of $276.80 million for the quarter, compared to analyst estimates of $254.41 million. During the same period in the prior year, the business earned $0.29 earnings per share. Omnicell’s quarterly revenue was down 7.4% on a year-over-year basis. Sell-side analysts forecast that Omnicell will post 0.64 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on OMCL shares. Bank of America reiterated a “neutral” rating and set a $57.00 target price (up from $44.00) on shares of Omnicell in a research report on Thursday. Barclays increased their price objective on shares of Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a report on Thursday. Wells Fargo & Company increased their price objective on shares of Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a report on Monday, October 14th. JPMorgan Chase & Co. increased their price objective on shares of Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a report on Friday, August 23rd. Finally, Benchmark restated a “buy” rating and issued a $48.00 price objective on shares of Omnicell in a report on Wednesday, October 9th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, Omnicell currently has an average rating of “Hold” and a consensus price target of $49.14.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.